Advertisement

Topics

Fusion Antibodies 'turn a curve' post-IPO

10:42 EST 28 Nov 2018 | Proactive Investors

Paul Kerr, CEO of Fusion Antibodies(LON:FAB) tells Proactive London about the strength of the company's board and how they're 'back in the game' post IPO.

Original Article: Fusion Antibodies 'turn a curve' post-IPO

NEXT ARTICLE

More From BioPortfolio on "Fusion Antibodies 'turn a curve' post-IPO"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...